4 Healthcare Stock Stories Making Tracks on Monday

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS): Closing price $31.81

On Monday, Biogen IDEC and Isis announced that they will work jointly to leverage antisense tech in the advancement of the treatment of neurological diseases. The accord unites Biogen Idec’s expertise in neurology with Isis’ leadership in antisense tech to develop novel therapies through which to treat neurological disorders. This marks the fourth collaboration between the firms in the last two years. As part of the six-year research collaboration, Biogen Idec will obtain exclusive rights to the use of Isis’ antisense tech to develop therapies for neurological diseases.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ISIS-20130909

Express Scripts Holding Co. (NASDAQ:ESRX): Closing price $64.77

Express Scripts announced Monday its strategic purchase of the SmartD Medicare Prescription Drug Plan, which contribute some 87,000 covered Medicare lives. The buyer serves millions of Medicare beneficiaries on behalf of its health plans, its Employer Group Waiver Plan clients, as well as through its own national Express Scripts Medicare PDP, which has consistently earned high Center for Medicare Services Star Ratings. This year, the plan earned four out of five possible stars, which is the highest of any nationally offered PDP. Terms of the transaction were not reported.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ESRX-20130909

Sanofi-Aventis (NYSE:SNY): Closing price $48.26

The designer, developer and maker of injectable drug delivery systems Unilife Corp., on Monday announced the signing of a long-term supply contract with Sanofi. Unilife will provide Sanofi with the Unifill Finesse, a customized device from its Unifill platform of prefilled syringes with automatic, needle retraction, for use with the anti-thrombotic therapy Enoxaparin Sodium sold under the brand names Lovenox and Clexane. The contract period may be extended up to 2024. Also, Unilife has granted Sanofi the exclusive use of the Unifill Finesse with anti-thrombotic drugs during the contract period.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

SNY-20130909

Theragenics Corp. (NYSE:TGX): Closing price $2.18

Theragenics announced Monday the expiration of the 35-day go-shop period through to the terms of the previously announced merger agreement, providing for a newly-created affiliate of Juniper Investment Company, LLC to purchase all of the outstanding common stock of the firm for $2.20 per share in cash. Theragenics is a medical device firm serving the surgical products and prostate cancer treatment markets.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

TGX-20130909

Don’t Miss: Who Can Profit from Johnson & Johnson’s Blood Test Business?